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Letters to the Editorto achieve polarized arrest that reduces
(1) Naþ and Ca2þ loading, (2) vasocon-
striction, (3) endothelial dysfunction,
(4) reperfusion arrhythmias, and (5)
contractile stunning.2 In the 1990s,
adenosine triphosphate–sensitive Kþ
channel openers provided initial hope
for amethod to induce polarized arrest3;
however, severe post-arrest arrhythmias
thwarted clinical adoption.
The clinical study by Jakobsen and
colleagues1 tested the hypothesis that
cold 1.2 mmol/L adenosine crystalloid
cardioplegia can achieve polarized ar-
rest and provide superior cardioprotec-
tion compared with a 20 mmol/L
hyperkalemic solution in low-risk pa-
tients. Their study found that adenosine
cardioplegia arrested the heart faster, re-
duced the incidence of atrial fibrillation
by more than 50%, and was associated
with lower postoperative plasma Kþ
levels. There were no differences in
postoperative troponin T, creatine
kinase-MB, creatinine, hemodynamics,
cardiac index, or endothelial activation.1
Adenosine has been investigated as
a potential cardioprotective agent in
cardiac surgery during the past several
decades. In 1989, Schubert and col-
leagues4 were the first to show that 10
mmol/L of adenosine rapidly arrested
the heart. However, persistent atrioven-
tricular block4 precluded its further de-
velopment as a polarizing arresting
agent, and it became an adjunct to
supranormal potassium.5 During the
past 20 years, the benefits of adjunctive
adenosine (<2mmol/L) in cardioplegia
have been mixed, ranging frommodest
effects5 to no benefits at all.6 The proto-
col reported by Jakobsen and col-
leagues1 used 1.2 mmol/L adenosine
to achieve polarized arrest. However,
this concentration is approximately
one tenth that used in earlier studies
in which adenosine was the primary ar-
resting agent.4 This discrepancy raises
an important question ofwhether aden-
osine is really the sole arresting agent in
Jakobsen’s study.
In 2004, Dobson and Jones7 re-
ported that adenosine (0.2 mmol/L)
and lidocaine (0.5 mmol/L) (AL) inThe Journala modified Krebs–Henseleit solution
arrested the heart in a polarized state,
with significantly improved func-
tional recoveries compared with St
Thomas’ solution. Although both
lidocaine and procaine are Naþ fast-
channel blockers, lidocaine was cho-
sen in AL cardioplegia because as
a class 1B antiarrhythmic, it shortens
repolarization time, whereas procaine
(class 1A) prolongs repolarization
time, which may cause postoperative
reanimation irritability. The AL con-
cept of polarized arrest was subse-
quently confirmed in the canine
model of cardiopulmonary bypass.8
Therefore, the efficacy of adenosine
cardioplegia in the study by Jakobsen
and colleagues1 could be due to its
combination with procaine. Whether
adenosine acted alone or not is impor-
tantbecause future studies testing aden-
osine as theprimaryarresting agentwill
derive their impetus from studies such
as the one by Jakobsen and colleagues.1
Precedence has been set for a polarized
alternative using adenosine and local
anesthetic (eg, lidocaine), which is the
proprietary composition ofHibernation
Therapeutics Global, Inc (Wicklow,
Ireland) and is trademarked and avail-
able asAdenocaine in theUnited States
from Central Admixture Pharmacy
Services (Kent, Wash). A recent pro-
spective randomized trial in Verona,
Italy, showed superiority of an AL car-
dioplegic formulation in high-risk pa-
tients compared with a 4:1 Buckberg
solution9; further clinical confirmation
for use ofALas a primary arresting for-
mulation that extends the data of Cor-
vera and colleagues8 is forthcoming.
The good news is that these studies col-
lectively give hope that an alternative to
supranormal potassium cardioplegia is
on the horizon for the good of low-
and high-risk pediatric and adult pa-
tients alike.
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We greatly appreciate the interest
by Drs Vinten Johansen and Dobson
in our article showing the efficacy
and beneficial impact of adenosine in-
stead of hyperkalemia in cold crystal-
loid cardioplegia. Their comments
raise interesting and relevant questions
regarding adenosine in cardioplegiay c Volume 145, Number 6 1685
Letters to the Editoras an arresting and cardioprotective
agent, and the concomitant use of
a local anesthetic.
A major object of our study was to
investigate whether this combination
was efficient in normokalemic cardio-
plegia, because possible negative ef-
fects of hyperkalemia have been
debated for decades and normokale-
mic adenosine/local anesthetic cardio-
plegia has been shown to be superior
in animal studies, compared with
both high and moderate potassium
concentrations.1 Despite some clinical
studies with the use of adenosine in
the cardioplegic solution, to our
knowledge, this is the first study on
the use of normokalemia.
As for the choice of local anes-
thetic, we used procaine because our
standard hyperkalemic cardioplegia
derived from St Thomas’ Hospital so-
lution contains 1 mmol/L of procaine
to reduce the group differences. Both
procaine and lidocaine reduce the ac-
tion potential amplitude and the max-
imum rate of increase of the upstroke
of the action potential, but they differ
in the influence of the action potential
duration (APD), where procaine in-
creases and lidocaine shortens the
APD. They both have rhythm-
stabilizing effects after cardiac sur-
gery. Cardioprotective properties,
although dose-dependent, have been
demonstrated for both drugs in iso-
lated heart studies.2 Although larger
clinical studies exclusively compar-
ing these 2 local anesthetics in cardi-
oplegia are missing, we agree that
adenosine-procaine and adenosine-
lidocaine cardioplegia are probably 2
sides of the same coin.
What is most important in achiev-
ing cardioplegic arrest: adenosine,
magnesium, or Naþ channel blockers,
such as lidocaine or procaine? Hypo-
thermia is the largest contributor to
the arrest, and infusing 750 mL of
cold crystalloid solution is going to ar-
rest the heart almost regardless of
composition. Whether this solution
will protect the heart while in its1686 The Journal of Thoracic andresting state or not is another matter.
It is not a given that cardiac arrest
and cardiac protection are equivalent.
Biochemical processes are highly
temperature-dependent, and little re-
search has been done to assess the be-
havior of drugs in hypothermic
conditions like the heart is in cardiac
surgery. We have previously shown
that hypothermia actually reversed
the APD shortening of adenosine tri-
phosphate–sensitive Kþ (KATP) chan-
nel openers, thus theoretically
making the KATP channel openers
less effective in achieving cardiac ar-
rest under hypothermic conditions.
Nevertheless, the KATP openers pro-
vided cardioprotective properties
even in hypothermic conditions.3 We
also previously showed that adenosine
has no effect on ventricular contractil-
ity at normothermia, whereas 1.2
mmol/L of adenosine significantly re-
duces contractile force at moderate
(24C) hypothermia.4
There are now several promising
studies from the use of adenosine in
cardioplegia, so alternatives to potas-
sium arrest may be in the making.
However, several issues still should
be addressed regarding the composi-
tion, optimal doses, type of delivery,
and vehicle. For instance, what are
the optimal dose, temperature, and ad-
ministration of adenosine in crystal-
loid and blood cardioplegia? What is
the role of adenosine in precondition-
ing? Steensrud and colleagues5 have
shown that adenosine can induce re-
mote preconditioning when given
intra-arterially, but not intravenously,
and that this effect is dependent on
an intact nerve system but inhibited
by nitric oxide. Thus, concomitant
medications, such as nitric oxide
donors or sulfonylureas and even an-
esthesia, may play a role in the search
of improving the current cardiopro-
tective solution. In the future, we
may be able to individualize our car-
dioplegic strategy according to the pa-
tient’s needs, that is, if alternatives
exist.Cardiovascular Surgery c June 2013Øyvind Jakobsen, MD, PhD
Tor Steensrud, MD, PhD
Department of Cardiothoracic and
Vascular Surgery
University Hospital of North Norway
Tromsø, Norway
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REPAIR: NEW OR RENAMED?
To the Editor:
It was with great interest that we
read the article by Tsukui and col-
leagues1 on early outcome of the fold-
ing mitral valve repair technique
without resection for mitral valve pro-
lapse in 60 patients. This folding
mitral valve repair technique—or
FMVR, as the authors call it—is de-
scribed as a non-resectional technique
with inversion of the prolapsed seg-
ment into the left ventricle and ring
annuloplasty, also applied for prolapse
secondary to ruptured chordae. The
authors apply a pilot stitch vertically
to the edge of the prolapsed segment
of the posterior leaflet, and additional
